Zobrazeno 1 - 10
of 293
pro vyhledávání: '"Pean E"'
Publikováno v:
In ESMO Open April 2021 6(2)
Autor:
Araujo-Fernandez, I., Delgado, J., Moscetti, L., Sarac, S.B., Zander, H., Mueller-Egert, S., Dunder, K., Pean, E., Bergmann, L., Enzmann, H., Pignatti, F.
Publikováno v:
In ESMO Open February 2021 6(1)
Autor:
Billingham L; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, UK. Electronic address: L.J.Billingham@bham.ac.uk., Brown L; Oncology Division, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: lynn.may.brown@merck.com., Framke T; European Medicines Agency, Amsterdam, The Netherlands. Institute for Biostatistics, Hannover Medical School, Hannover, Germany. Electronic address: theodor.framke@ema.europa.eu., Greystoke A; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: Alastair.greystoke@newcastle.ac.uk., Hovig E; Centre for Bioinformatics, University of Oslo, P.O. Box 1080 Blindern, 0316 OSLO, Norway; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway. Electronic address: ehovig@ifi.uio.no., Mathur S; Oncology Division, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: siddhartha.mathur@merck.com., Page P; Human Colossus Foundation, Switzerland. Electronic address: philippe.page@humancolossus.org., Pean E; European Medicines Agency, Amsterdam, the Netherlands. Electronic address: elias.pean@ema.europa.eu., Barjesteh van Waalwijk van Doorn-Khosrovani S; National Funder's Committee for Evaluation of Specialised Medicines and Companion Diagnostics (CieBAG), the Netherlands; Department of Oncology, Leiden University Medical Centre The Netherlands CZ, Postbus 90152, 5000 LD, Tilburg, the Netherlands. Electronic address: sahar.van.waalwijk@cz.nl., Vonk R; Bayer AG 13342 Berlin, Germany. Electronic address: richardus.vonk@bayer.com., Wissink S; Merck Sharpe Dohme, the Netherlands. Electronic address: sacha.wissink@merck.com., Zander H; Paul-Elrich Institut, Germany. Electronic address: hilke.zander@pei.de., Plummer R; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: ruth.plummer@ncl.ac.uk.
Publikováno v:
Cancer treatment reviews [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102674. Date of Electronic Publication: 2023 Dec 23.
Autor:
Mulder J; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Verjans R; Lygature, Utrecht, Netherlands., Verbaanderd C; European Medicines Agency, Amsterdam, Netherlands.; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Pean E; European Medicines Agency, Amsterdam, Netherlands., Weemers J; Janssen Biologics BV, Leiden, Netherlands., Leufkens HGM; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands., Pignatti F; European Medicines Agency, Amsterdam, Netherlands., de Boer A; Dutch Medicines Evaluation Board, Utrecht, Netherlands.; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands., Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Stoyanova-Beninska VV; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Pasmooij AMG; Dutch Medicines Evaluation Board, Utrecht, Netherlands.
Publikováno v:
Frontiers in medicine [Front Med (Lausanne)] 2021 Dec 09; Vol. 8, pp. 790782. Date of Electronic Publication: 2021 Dec 09 (Print Publication: 2021).
Publikováno v:
Agris On-Line Papers in Economics & Informatics. Dec2020, Vol. 12 Issue 4, p61-76. 16p.
Autor:
Eichler HG; Regulatory Science and Innovation Task Force, European Medicines Agency (EMA), Amsterdam, The Netherlands.; Medical University of Vienna, Vienna, Austria., Adams R; National Centre for Pharmacoeconomics (NCPE Ireland), Dublin, Ireland.; Trinity College Dublin, Dublin, Ireland., Andreassen E; Statens Legemiddelverk (SLV), Oslo, Norway., Arlett P; Data Analytics and Methods Task Force, European Medicines Agency (EMA), Amsterdam, The Netherlands.; London School of Hygiene and Tropical Medicine, London, UK., van de Casteele M; Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance (NIHDI/RIZIV/INAMI), Brussels, Belgium., Chapman SJ; Organisation for Economic Co-operation and Development (OECD), Paris, France., Goettsch WG; National Health Care Institute (ZIN), Diemen, The Netherlands.; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Martinsson JL; Department of Value Based Pricing, Tandvårds- och läkemedelsförmånsverket (TLV), Stockholm, Sweden., Llinares-Garcia J; Regulatory Science and Innovation Task Force, European Medicines Agency (EMA), Amsterdam, The Netherlands., Nachtnebel A; Dachverband der Sozialversicherungsträger (DVSV), Vienna, Austria., Pean E; Office of Oncology and Haematology, European Medicines Agency (EMA), Amsterdam, The Netherlands., Rasi G; European Medicines Agency, Amsterdam, The Netherlands.; Department of Experimental Medicine, Universita di Tor Vergata, Rome, Italy., Reksten TR; Statens Legemiddelverk (SLV), Oslo, Norway., Timmers L; National Health Care Institute (ZIN), Diemen, The Netherlands., Vreman RA; National Health Care Institute (ZIN), Diemen, The Netherlands.; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., van de Vijver I; Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance (NIHDI/RIZIV/INAMI), Brussels, Belgium., Wenzl M; Organisation for Economic Co-operation and Development (OECD), Paris, France.
Publikováno v:
International journal of technology assessment in health care [Int J Technol Assess Health Care] 2021 Aug 23; Vol. 37 (1), pp. e83. Date of Electronic Publication: 2021 Aug 23.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
[Rapport Technique] UMR 6566 CReAAH; INRAP GO, Cesson-Sévigné. 2016, 29 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::169f933c402e00c13b083acdb4dd636a
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02483184
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02483184
Autor:
Ali S; European Medicines Agency, Amsterdam, Netherlands., Camarero J; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain., Hennik P; Medicines Evaluation Board, Utrecht, Netherlands., Bolstad B; Norwegian Medicines Agency, Oslo, Norway., Sommerfelt Grønvold M; Norwegian Medicines Agency, Oslo, Norway., Syvertsen C; Norwegian Medicines Agency, Oslo, Norway., Oddvar Strøm B; Norwegian Medicines Agency, Oslo, Norway., Ökvist M; Norwegian Medicines Agency, Oslo, Norway., Josephson F; Medical Products Agency, Uppsala, Sweden., Keller-Stanislawski B; Paul-Ehrlich-Institute, Langen, Germany., Zafiropoulos N; European Medicines Agency, Amsterdam, Netherlands., Pean E; European Medicines Agency, Amsterdam, Netherlands., Bergh J; Radiumhemmet Microbiology and Tumorbiology Center, Karolinska University Hospital, Stockholm, Sweden., da Rocha Dias S; European Medicines Agency, Amsterdam, Netherlands. Electronic address: silvy.darochadias@ema.europa.eu., Pignatti F; European Medicines Agency, Amsterdam, Netherlands.
Publikováno v:
ESMO open [ESMO Open] 2020 Nov; Vol. 5 (6), pp. e000798.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.